File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus
  • Basic View
  • Metadata View
  • XML View
TitleSerum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus
 
AuthorsMok, MY1
Huang, FP3
Ip, WK4
Lo, Y1
Wong, FY4
Chan, EYT4
Lam, KF1
Xu, D2
 
KeywordsInterleukin-33
Soluble ST2
Systemic lupus erythematosus disease activity index
T helper 2 immune response
 
Issue Date2009
 
PublisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/
 
CitationRheumatology, 2009, v. 49 n. 3, p. 520-527 [How to Cite?]
DOI: http://dx.doi.org/10.1093/rheumatology/kep402
 
AbstractObjective. IL-33 has recently been found to be the specific ligand of ST2, an IL-1 receptor family member that is selectively expressed in Th2 cells and mediates Th2 response. This study aims to measure the serum levels of soluble ST2 (sST2) and IL-33 in patients with SLE and to examine their association with disease activity. Methods. Seventy SLE patients were evaluated for disease activity, determined by SLEDAI, levels of anti-dsDNA antibody, C3 and C4. Fifty-seven patients were evaluated longitudinally on a second occasion. IL-33 and sST2 were measured by sandwich ELISA in the 127 SLE serum samples and compared with 28 age-and sex-matched healthy controls. Results. Serum sST2 level was significantly higher in active SLE patients [0.51 (0.18) ng/ml] compared with inactive patients [0.42 (0.08) ng/ml] (P = 0.006) and normal controls [0.36 (0.13) ng/ml] (P<0.001). sST2 level correlated significantly with SLEDAI, anti-dsDNA antibody and prednisolone dosage, and negatively with C3. Linear regression analysis showed that serum sST2 level was an independent predictive factor for modified SLEDAI, excluding anti-dsDNA and complement score after controlling for age, sex, glomerular filtration rate and prednisolone dosage (regression coefficient: 8.5; 95% CI 2.6, 14.3) (P = 0.005). Serum sST2 level was sensitive to change in disease activity longitudinally, with an effect size of 0.29. Elevated serum IL-33 was comparable in frequency (4.3 vs 7.1%; P = 0.62) and levels (P = 0.53) between SLE patients and controls. Conclusions. Elevated serum sST2 level in SLE patients was found to correlate with disease activity and was sensitive to change, suggesting a potential role as a surrogate marker of disease activity. © The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology.
 
ISSN1462-0324
2013 Impact Factor: 4.435
 
DOIhttp://dx.doi.org/10.1093/rheumatology/kep402
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorMok, MY
 
dc.contributor.authorHuang, FP
 
dc.contributor.authorIp, WK
 
dc.contributor.authorLo, Y
 
dc.contributor.authorWong, FY
 
dc.contributor.authorChan, EYT
 
dc.contributor.authorLam, KF
 
dc.contributor.authorXu, D
 
dc.date.accessioned2012-09-05T05:29:50Z
 
dc.date.available2012-09-05T05:29:50Z
 
dc.date.issued2009
 
dc.description.abstractObjective. IL-33 has recently been found to be the specific ligand of ST2, an IL-1 receptor family member that is selectively expressed in Th2 cells and mediates Th2 response. This study aims to measure the serum levels of soluble ST2 (sST2) and IL-33 in patients with SLE and to examine their association with disease activity. Methods. Seventy SLE patients were evaluated for disease activity, determined by SLEDAI, levels of anti-dsDNA antibody, C3 and C4. Fifty-seven patients were evaluated longitudinally on a second occasion. IL-33 and sST2 were measured by sandwich ELISA in the 127 SLE serum samples and compared with 28 age-and sex-matched healthy controls. Results. Serum sST2 level was significantly higher in active SLE patients [0.51 (0.18) ng/ml] compared with inactive patients [0.42 (0.08) ng/ml] (P = 0.006) and normal controls [0.36 (0.13) ng/ml] (P<0.001). sST2 level correlated significantly with SLEDAI, anti-dsDNA antibody and prednisolone dosage, and negatively with C3. Linear regression analysis showed that serum sST2 level was an independent predictive factor for modified SLEDAI, excluding anti-dsDNA and complement score after controlling for age, sex, glomerular filtration rate and prednisolone dosage (regression coefficient: 8.5; 95% CI 2.6, 14.3) (P = 0.005). Serum sST2 level was sensitive to change in disease activity longitudinally, with an effect size of 0.29. Elevated serum IL-33 was comparable in frequency (4.3 vs 7.1%; P = 0.62) and levels (P = 0.53) between SLE patients and controls. Conclusions. Elevated serum sST2 level in SLE patients was found to correlate with disease activity and was sensitive to change, suggesting a potential role as a surrogate marker of disease activity. © The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationRheumatology, 2009, v. 49 n. 3, p. 520-527 [How to Cite?]
DOI: http://dx.doi.org/10.1093/rheumatology/kep402
 
dc.identifier.doihttp://dx.doi.org/10.1093/rheumatology/kep402
 
dc.identifier.epage527
 
dc.identifier.issn1462-0324
2013 Impact Factor: 4.435
 
dc.identifier.issue3
 
dc.identifier.pmid20026564
 
dc.identifier.scopuseid_2-s2.0-77950534152
 
dc.identifier.spage520
 
dc.identifier.urihttp://hdl.handle.net/10722/163300
 
dc.identifier.volume49
 
dc.languageeng
 
dc.publisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofRheumatology
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdult
 
dc.subject.meshAntibodies, Antinuclear - Blood
 
dc.subject.meshBiological Markers - Blood
 
dc.subject.meshDose-Response Relationship, Drug
 
dc.subject.meshEpidemiologic Methods
 
dc.subject.meshFemale
 
dc.subject.meshGlucocorticoids - Administration & Dosage
 
dc.subject.meshHumans
 
dc.subject.meshImmunosuppressive Agents - Administration & Dosage
 
dc.subject.meshInterleukins - Blood
 
dc.subject.meshLupus Erythematosus, Systemic - Drug Therapy - Immunology
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshPrednisolone - Administration & Dosage
 
dc.subject.meshReceptors, Cell Surface - Blood
 
dc.subjectInterleukin-33
 
dc.subjectSoluble ST2
 
dc.subjectSystemic lupus erythematosus disease activity index
 
dc.subjectT helper 2 immune response
 
dc.titleSerum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Mok, MY</contributor.author>
<contributor.author>Huang, FP</contributor.author>
<contributor.author>Ip, WK</contributor.author>
<contributor.author>Lo, Y</contributor.author>
<contributor.author>Wong, FY</contributor.author>
<contributor.author>Chan, EYT</contributor.author>
<contributor.author>Lam, KF</contributor.author>
<contributor.author>Xu, D</contributor.author>
<date.accessioned>2012-09-05T05:29:50Z</date.accessioned>
<date.available>2012-09-05T05:29:50Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>Rheumatology, 2009, v. 49 n. 3, p. 520-527</identifier.citation>
<identifier.issn>1462-0324</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/163300</identifier.uri>
<description.abstract>Objective. IL-33 has recently been found to be the specific ligand of ST2, an IL-1 receptor family member that is selectively expressed in Th2 cells and mediates Th2 response. This study aims to measure the serum levels of soluble ST2 (sST2) and IL-33 in patients with SLE and to examine their association with disease activity. Methods. Seventy SLE patients were evaluated for disease activity, determined by SLEDAI, levels of anti-dsDNA antibody, C3 and C4. Fifty-seven patients were evaluated longitudinally on a second occasion. IL-33 and sST2 were measured by sandwich ELISA in the 127 SLE serum samples and compared with 28 age-and sex-matched healthy controls. Results. Serum sST2 level was significantly higher in active SLE patients [0.51 (0.18) ng/ml] compared with inactive patients [0.42 (0.08) ng/ml] (P = 0.006) and normal controls [0.36 (0.13) ng/ml] (P&lt;0.001). sST2 level correlated significantly with SLEDAI, anti-dsDNA antibody and prednisolone dosage, and negatively with C3. Linear regression analysis showed that serum sST2 level was an independent predictive factor for modified SLEDAI, excluding anti-dsDNA and complement score after controlling for age, sex, glomerular filtration rate and prednisolone dosage (regression coefficient: 8.5; 95% CI 2.6, 14.3) (P = 0.005). Serum sST2 level was sensitive to change in disease activity longitudinally, with an effect size of 0.29. Elevated serum IL-33 was comparable in frequency (4.3 vs 7.1%; P = 0.62) and levels (P = 0.53) between SLE patients and controls. Conclusions. Elevated serum sST2 level in SLE patients was found to correlate with disease activity and was sensitive to change, suggesting a potential role as a surrogate marker of disease activity. &#169; The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology.</description.abstract>
<language>eng</language>
<publisher>Oxford University Press. The Journal&apos;s web site is located at http://rheumatology.oxfordjournals.org/</publisher>
<relation.ispartof>Rheumatology</relation.ispartof>
<subject>Interleukin-33</subject>
<subject>Soluble ST2</subject>
<subject>Systemic lupus erythematosus disease activity index</subject>
<subject>T helper 2 immune response</subject>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Antibodies, Antinuclear - Blood</subject.mesh>
<subject.mesh>Biological Markers - Blood</subject.mesh>
<subject.mesh>Dose-Response Relationship, Drug</subject.mesh>
<subject.mesh>Epidemiologic Methods</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Glucocorticoids - Administration &amp; Dosage</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Immunosuppressive Agents - Administration &amp; Dosage</subject.mesh>
<subject.mesh>Interleukins - Blood</subject.mesh>
<subject.mesh>Lupus Erythematosus, Systemic - Drug Therapy - Immunology</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Prednisolone - Administration &amp; Dosage</subject.mesh>
<subject.mesh>Receptors, Cell Surface - Blood</subject.mesh>
<title>Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1093/rheumatology/kep402</identifier.doi>
<identifier.pmid>20026564</identifier.pmid>
<identifier.scopus>eid_2-s2.0-77950534152</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77950534152&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>49</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>520</identifier.spage>
<identifier.epage>527</identifier.epage>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. University of Glasgow
  3. Imperial College London
  4. Queen Mary Hospital Hong Kong